Pfizer Inc. $PFE Shares Purchased by Jacobi Capital Management LLC

Jacobi Capital Management LLC boosted its stake in Pfizer Inc. (NYSE:PFE) by 3.4% during the first quarter, Holdings Channel.com reports. The fund owned 129,201 shares of the biopharmaceutical company’s stock after purchasing an additional 4,285 shares during the quarter. Jacobi Capital Management LLC’s holdings in Pfizer were worth $3,274,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Gould Capital LLC grew its stake in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 493 shares during the period. GKV Capital Management Co. Inc. purchased a new position in Pfizer in the 1st quarter valued at $27,000. North Capital Inc. purchased a new position in Pfizer in the 1st quarter valued at $28,000. Bayforest Capital Ltd purchased a new position in Pfizer in the 1st quarter valued at $28,000. Finally, Bernard Wealth Management Corp. purchased a new position in Pfizer in the 4th quarter valued at $30,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Jefferies Financial Group raised their price objective on Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a report on Wednesday, May 21st. Morgan Stanley raised their price objective on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a report on Wednesday, August 6th. Berenberg Bank decreased their price objective on Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a report on Thursday, May 29th. Bank of America raised their price objective on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Finally, HSBC decreased their price objective on Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a report on Monday, May 19th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $28.12.

Pfizer Stock Down 0.5%

NYSE PFE opened at $24.59 on Thursday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The business’s fifty day simple moving average is $24.83 and its 200-day simple moving average is $24.33. The firm has a market cap of $139.79 billion, a PE ratio of 13.08, a P/E/G ratio of 0.88 and a beta of 0.55.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the previous year, the firm earned $0.60 EPS. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.0%. The ex-dividend date was Friday, July 25th. Pfizer’s payout ratio is 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.